Drug intelligence / Profile preview

ST-1891

Development stage: Phase 2
Lead developer: Sention Therapeutics
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

ST-1891 is a novel, oral small molecule investigational drug developed for the treatment of hypothyroidism. It functions as a hormone replacement therapy by replacing decreased T3 and T4 thyroid hormone levels in patients with hypothyroidism. The drug has completed four Phase 1 clinical studies in healthy adult volunteers and has advanced to Phase 2 clinical trials, where it is being evaluated against levothyroxine (Euthyrox) in patients with primary hypothyroidism. The developer is Sention Therapeutics.

Targets

THR (Thyroid hormone receptor)

Beyond the preview

Go deeper on ST-1891.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-1891.

Explore the full profile